Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Colorcon
Moodys
Merck
Medtronic

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DURVALUMAB

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for durvalumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01693562 A Phase 1/2 Study to Evaluate MEDI4736 Active, not recruiting MedImmune LLC Phase 1/Phase 2 2012-08-01 This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors. An exploration cohort has been added to determine the safety using Q4W dosing.
NCT01975831 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Recruiting Cancer Research Institute, New York City Phase 1 2013-12-01 This is a multicenter, open-label, study with a standard 3+3 dose-escalation phase, followed by an expansion phase in subjects with solid tumors
NCT01975831 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Recruiting MedImmune LLC Phase 1 2013-12-01 This is a multicenter, open-label, study with a standard 3+3 dose-escalation phase, followed by an expansion phase in subjects with solid tumors
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for durvalumab

Condition Name

Condition Name for durvalumab
Intervention Trials
Non-small Cell Lung Cancer 18
Breast Cancer 13
Carcinoma, Non-Small-Cell Lung 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for durvalumab
Intervention Trials
Lung Neoplasms 58
Carcinoma, Non-Small-Cell Lung 54
Carcinoma 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for durvalumab

Trials by Country

Trials by Country for durvalumab
Location Trials
United States 697
Canada 79
United Kingdom 48
Spain 45
Korea, Republic of 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for durvalumab
Location Trials
New York 66
Texas 46
California 38
Florida 33
Massachusetts 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for durvalumab

Clinical Trial Phase

Clinical Trial Phase for durvalumab
Clinical Trial Phase Trials
Phase 4 1
Phase 3 22
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for durvalumab
Clinical Trial Phase Trials
Not yet recruiting 157
Recruiting 127
Active, not recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for durvalumab

Sponsor Name

Sponsor Name for durvalumab
Sponsor Trials
AstraZeneca 156
MedImmune LLC 32
National Cancer Institute (NCI) 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for durvalumab
Sponsor Trials
Other 281
Industry 259
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Colorcon
Harvard Business School
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.